Publications

5901 Results

Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163

Authors
Saba NF;Flamand Y;Lin DT;Chung CH;McDonald MW;Flampouri S;Khan SA;Snyderman CH;Hanna EY;El-Sayed IH;Solares CA;Le CH;Ghaly M;Hwang PH;Shin DM;Axelrod RS;Ikpeazu CV;Adkins DR;Duan F;Cohen M;Samuels MA;Swiecicki PL;Subramaniam RM;Chakravarthy AB;Burtness BA
Journal / Conference
Clin Cancer Res. 2025 Jun 13;31(12):2339-2346. doi: 10.1158/1078-0432.CCR-24-4085.NIHMS2075936
Year
2025
PMID
PMID40227186
PMC
PMC12165817

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Authors
Shanafelt TD;Wang XV;Hanson CA;Paietta E;O’Brien S;Barrientos J;Jelinek DF;Braggio E;Leis JF;Zhang CC;Barr PM;Cashen AF;Mato AR;Singh AK;Mullane MP;Little RF;Erba H;Stone RM;Litzow M;Tallman M;Kay NE
Journal / Conference
Blood Adv. 2025 Jan 14;9(1):224-228. doi: 10.1182/bloodadvances.2024013474
Year
2025
Research Committee(s)
Leukemia
PMID
PMID39163612
PMC
PMC11788128
Study Number(s)
CTSU/E1912

Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Authors
Tarhini AA;Obermayer A;Lee SJ;LaFramboise WA;Hodi FS;Karunamurthy AD;Eljilany I;Chen DT;Hwu P;El Naqa IM;Streicher H;Sondak VK;Storkus WJ;Butterfield LH;Shaw TI;Kirkwood JM
Journal / Conference
Clin Cancer Res. 2025 Aug 1;31(15):3249-3258. doi: 10.1158/1078-0432.CCR-24-3980. NIHMS2085262
Year
2025
Research Committee(s)
Melanoma
PMID
PMID40392969
PMC
PMC12316551
Study Number(s)
CTSU/E1609

CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists

Authors
Uehara Y;Nishizaki D;Fujiwara Y;Miyashita H;Lee S;Pabla S;DePietro P;Ko H;Jensen TJ;Sicklick JK;Kato S;Kurzrock R
Journal / Conference
Cancer Immunol Immunother. 2025 Nov 3;74(12):359. doi: 10.1007/s00262-025-04197-8
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41182434
PMC
PMC12583269

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

Authors
Wang X;Li T;Eljilany I;Soupir A;Radmacher M;Agius P;Sukrithan V;Ratan A;McCarter M;Salhia B;Colman H;Naqash AR;Puzanov I;Arnold S;Marin-Acevedo JA;Ganesan S;Churchman M;Hwu P;Rodriguez PC;Dalton WS;Weiner GJ;Tarhini AA
Journal / Conference
Nat Commun. 2025 Nov 13;16(1):9968. doi: 10.1038/s41467-025-65016-3
Year
2025
Research Committee(s)
Melanoma
PMID
PMID41233329
PMC
PMC12615696
Study Number(s)
CTSU/E1609

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

Authors
Zandberg DP;Allred JB;Rosenberg AJ;Kaczmar JM;Swiecicki P;Julian RA;Poklepovic AS;Bauman JR;Phan MD;Saba NF;Rivera E;Rowland K;Davar D;Cordes J;Ho AL;Zhang M;Berg SA;Munster PN;Schwartz GK
Journal / Conference
J Clin Oncol. 2025 Jul 20;43(21):2398-2408. doi: 10.1200/JCO-25-00759. Epub 2025 May 31.NIHMS2079170
Year
2025
PMID
PMID40448574
PMC
PMC12677393

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. Reply

Authors
Herrera AF;LeBlanc M;Friedberg JW
Journal / Conference
N Engl J Med. 2025 Jan 2;392(1):102. doi: 10.1056/NEJMc2414269
Year
2025
Research Committee(s)
Lymphoma
PMID
PMID39752312
Study Number(s)
S1826

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

Authors
A Apolo;K Ballman;G Sonpavde;S Berg;W Kim;R Parikh;M Teo;R Sweis;D Geynisman;P Grivas;G Chatta;J Kim;M Bilen;B McGregor;P Singh;A Tripathi;S Cole;N Simon;S Niglio;L Ley;L Cordes;S Srinivas;J Huang;P Steen;M Odegaard;C Watt;D Petrylak;J Hoffman-Censits;Y Wen;O Hahn;C Mitchell;A Tan;H Streicher;E Sharon;H Moon;M Woods;S Halabi;G Burbano;M Morris;J Rosenberg
Journal / Conference
N Engl J Med. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15.NIHMS2021479
Year
2025
Research Committee(s)
Genitourinary
PMID
PMID39282902
PMC
PMC11698643
Study Number(s)
CTSU/A031501

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

Authors
E Bergsland;S Geyer;T Asmis;S Behr;P Kumthekar;M Maitland;D Niedzwiecki;A Nixon;L Schwartz;J Strosberg;A Venook;E O'Reilly;J Meyerhardt
Journal / Conference
J Clin Oncol. 2025 Oct 10;43(29):3170-3183. doi: 10.1200/JCO-24-02644. Epub 2025 Sep 3.NIHMS2099573
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID40902132
PMC
PMC12457709
Study Number(s)
CTSU/A021202

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Authors
B Andreadis;N Bartlett;J Leonard;P Stiff;J Friedberg;TBA
Journal / Conference
Leuk Lymphoma. 2025 Oct;66(10):1903-1912. doi: 10.1080/10428194.2025.2525982. Epub 2025 Jul 9.NIHMS2093959
Year
2025
Research Committee(s)
Lymphoma
PMID
PMID40632607
PMC
PMC12321088
Study Number(s)
CTSU/A051301